Digital Pharma Lab
Contact
Early and compassionate access in France (AAP, AAC): criteria, steps and link with reimbursement

Early and compassionate access in France (AAP, AAC): criteria, steps and link with reimbursement

Since the 2021 reform, early access and compassionate access have replaced the French ATU and RTU schemes. Criteria, stakeholders, steps and link with reimbursement.

November 18, 2026 · Digital Pharma Lab

Since 1 July 2021, two schemes have replaced the former temporary authorisations for use (ATU) and temporary recommendations for use (RTU): the early access authorisation (AAP), decided by the French National Authority for Health (HAS), and compassionate access, managed by the French National Agency for Medicines and Health Products Safety (ANSM). Early access concerns medicines presumed to be innovative, intended to be marketed and reimbursed in the indication. Compassionate access meets a medical need for medicines that are not the subject of commercial clinical research in the indication concerned, subject to a regulated exception.

Up to date as of 18 November 2026.

What did the 2021 reform change?

The Social Security Financing Act for 2021, through its article 78, overhauled the schemes for exceptional access to medicines. Decree No. 2021-869 of 30 June 2021 on early and compassionate access authorisations set out their arrangements, which have applied since 1 July 2021; Decree No. 2021-870 set the maximum durations and time limits (article D5121-69-3 of the French Public Health Code). These rules have since been amended, in particular by Decree No. 2026-448 of 3 June 2026, which has applied since 1 September 2026 (see article R5121-69).

The landscape has been simplified around two routes:

  1. early access, which takes over the logic of the former cohort ATUs and of the coverage that followed marketing authorisation (AMM): a promising medicine, which its company undertakes to market, is made available before the end of its authorisation or reimbursement process;
  2. compassionate access, which takes over that of the former named-patient ATUs and RTUs: it allows a patient to be treated, or a prescribing practice to be made safer, outside any commercial approach in the indication.

The HAS presents the early access scheme, its criteria, its doctrine and the filing arrangements on a dedicated page (in French).

What are the criteria for an early access authorisation?

Article L.5121-12 of the French Public Health Code, as worded by article 78 of the 2021 Social Security Financing Act, reserves early access for medicines intended to treat serious, rare or disabling diseases, when four conditions are met:

  1. there is no appropriate treatment;
  2. treatment cannot be postponed;
  3. the efficacy and safety of the medicine are strongly presumed on the basis of clinical trial results;
  4. the medicine is presumed to be innovative, in particular compared with a clinically relevant comparator, if any.

In addition, the company must commit to a filing timeline, depending on the medicine's stage. Without marketing authorisation in the indication, it has filed or undertakes to file a marketing authorisation application within a period set by the HAS, which may not exceed two years from the grant of the authorisation (article D5121-69-3). With marketing authorisation in the indication, the application for inclusion in reimbursement must be filed within one month of obtaining marketing authorisation (article 78 of the 2021 Social Security Financing Act).

In our experience, the innovation criterion is often the most debated. It is not enough for a medicine to be new: according to the HAS assessment doctrine, it must be likely to bring a substantial change for patients in their care, in terms of efficacy, safety, practicality or care pathway. This doctrine, updated since 2021, is published on the HAS website.

Who decides, and how does an application unfold?

The decision lies with the HAS in both situations provided for by law, but the circuit differs depending on whether the medicine already has a marketing authorisation in the indication.

Before marketing authorisation. The HAS decides after a binding opinion (avis conforme) from the ANSM on the strong presumption of efficacy and safety; an unfavourable ANSM opinion leads to refusal. Since 1 September 2026, this opinion is no longer required where the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion (article R5121-69, amended by Decree No. 2026-448 of 3 June 2026). Applications filed before that date remain governed by the previous rules.

After marketing authorisation. The medicine is authorised in the indication but not yet covered under the standard scheme. The HAS decides alone. The company files its application for inclusion in reimbursement within one month of obtaining marketing authorisation.

In both cases, the application follows similar steps:

  1. the company files its dossier electronically, through the single portal designated by ministerial order (article R5121-68), using the template dossiers published by the HAS, demonstrating each criterion;
  2. the HAS rules on administrative admissibility within 10 working days, according to its dedicated page;
  3. the ANSM gives a binding opinion, unless the CHMP has issued a positive opinion, for early access before marketing authorisation;
  4. the HAS communicates its reasoned decision within 90 days of acknowledging receipt of the complete dossier, extended by 30 days when the number of applications is exceptionally high (article R5121-69);
  5. the authorisation is granted for one year at most, renewable for at most one year at each renewal (article D5121-69-3), together with a therapeutic use and data collection protocol (PUT-RD);
  6. the company periodically submits the data collected and a summary report, which are used for renewal and, later, for the reimbursement dossier; the renewal application is sent no later than three months before the authorisation expires (article R5121-69-4).

The PUT-RD deserves particular attention. It sets the conditions of use, patient follow-up and real-world data collection. Well designed, it can feed into the subsequent assessment by the Transparency Committee.

How does early access fit with reimbursement?

During early access, the medicine is covered by the national health insurance. The company declares to the Economic Committee for Health Products (CEPS) the maximum indemnity it claims from healthcare institutions, and the CEPS publishes these declarations. Rebates are then due under the rules set by article L.162-16-5-1-1 of the French Social Security Code. As worded by article 78 of the 2021 Social Security Financing Act, this article provides for annual rebates calculated on a progressive scale by turnover bracket and then, upon inclusion in reimbursement, an additional rebate when turnover valued at the standard net price is lower than the turnover invoiced, or conversely a refund to the company, capped at the rebates already paid. The detailed arrangements are those of the version of the article in force and its implementing texts.

Early access is therefore not an end in itself. It is a step towards the standard scheme: assessment by the Transparency Committee (see our article on the transparency dossier), then price negotiation with the CEPS and, if the product is subject to it, the efficiency opinion of the Economic and Public Health Evaluation Committee (CEESP).

Two practical consequences follow:

  • the data collected during early access matter: they complement the trials and can shed light on the medicine's place in French practice;
  • the level of the indemnity should be set knowingly: a large gap with the price finally negotiated results in rebates to be paid back, which must be anticipated in the financial plan.

What is compassionate access?

Compassionate access, governed by article L.5121-12-1 of the French Public Health Code, falls under the ANSM. It requires that the medicine is not the subject of research involving human subjects for commercial purposes in the indication, that there is no appropriate treatment, and that its efficacy and safety are presumed on the basis of the available data. It takes two forms:

  • the compassionate access authorisation (AAC), granted by the ANSM for a named patient, at the request of their physician, for a medicine not authorised in the indication, for a maximum of one year, renewable;
  • the compassionate prescription framework (CPC), established by the ANSM for a medicine authorised in other indications, to make prescribing outside them safer, for three years, renewable.

The AAC has one exception: a medicine at a very early stage of research may benefit from it when treatment cannot be postponed and the patient cannot take part in the research, provided the rights holder undertakes to file an early access application. The time limit is 12 months at most from the grant of the AAC, extended to 18 months for a rare disease (article D5121-74-1-1, section on compassionate access authorisations).

For a company, the boundary with early access is structural. If commercial research is under way in the indication, early access is in principle the expected route, with its filing commitments. Compassionate access is not a lighter alternative to early access: it addresses a different situation.

What mistakes should be avoided?

In our experience, applications that become complicated often share the same weaknesses:

  • a poorly demonstrated innovation criterion, for lack of a clear comparison with existing options, including those used off-label;
  • a presumption of efficacy based on data that are too preliminary, or on an endpoint whose link with clinical benefit has not been established;
  • confusion between early access and compassionate access, which wastes time when patients are waiting;
  • a PUT-RD treated as a formality, whereas it determines the quality of the data available for what follows;
  • filing commitments poorly aligned with the product's actual regulatory timeline;
  • an indemnity set without a price scenario, which exposes the company to large rebates at the time of negotiation.

Where to start?

The decision to apply for early access is prepared well before filing: as soon as the first efficacy results suggest a major benefit, it is useful to test the product against the criteria of the Public Health Code, identify the clinically relevant comparator and outline the PUT-RD. For applications before marketing authorisation, the HAS and the ANSM offer optional, free and confidential pre-submission meetings, to be requested 2 to 3 months before filing; they do not constitute an assessment (HAS page).

An early access strategy is best designed together with the rest of the pathway: transparency dossier, health economics and, to save time on monitoring and dossier preparation, a governed use of AI, which we describe in what AI changes in market access.

This article provides general information; it does not replace regulatory advice tailored to your product. For support with an early access strategy, discover our market access expertise.

Sources

Sources accessed on 18 November 2026.

Our expertise on this topic

  • Market Access

    Building robust access strategies, solid health-economic evaluations, and HAS dossiers that withstand scrutiny.